Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | ETV6 | P41212 | 3/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 4/20 | 0.33 |
| ▸ | ATR | Q13535 | 5/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.30 |
| ▸ | NPM1 | P06748 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30713474 | 0.88 | KDR (0.42) | CYP4F2CYP4A11KDRETV6JAK2 | |
| SCHEMBL31536713 | 0.88 | CYP4F2 (0.35) | CYP4F2CYP4A11KDRETV6RET | |
| SCHEMBL31484973 | 0.87 | RET (0.35) | CYP4F2CYP4A11KDRETV6RET | |
| SCHEMBL30713519 | 0.85 | FGFR4 (0.34) | KDRETV6RETATR | |
| SCHEMBL29092373 | 0.85 | CYP4F2 (0.33) | CYP4F2CYP4A11KDRETV6RET | |
| SCHEMBL27187897 | 0.85 | CYP4F2 (0.33) | CYP4F2CYP4A11KDRETV6RET | |
| SCHEMBL27187892 | 0.85 | CYP4F2 (0.33) | CYP4F2CYP4A11KDRETV6RET | |
| SCHEMBL30713495 | 0.84 | KDR (0.35) | KDRETV6METATRJAK2 | |
| SCHEMBL30713473 | 0.84 | FGFR4 (0.32) | KDRRETMETJAK2DGAT2 | |
| SCHEMBL30178225 | 0.82 | KDR (0.41) | CYP4F2CYP4A11KDRETV6JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368666-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4547656-A1 | INDAZOLE COMPOUNDS | Tyra Biosciences, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119731165-A | Indazole compounds | 泰拉生物科学公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024006897-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368666-A1 | INDAZOLE COMPOUNDS | FGFR1, FGFR3, FGFR2 | CYP4F2 1319/4885CYP4A11 933/4885KDR 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.